This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignee: Novartis Ag. Active years: 2022-2026.
Company Filing History:
Years Active: 2022-2026
Title: James Edgar Chastain: Innovator in Anti-Betacellulin Antibodies
Introduction
James Edgar Chastain is a notable inventor based in Acton, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of anti-betacellulin antibodies. His work has implications for various therapeutic applications, showcasing his innovative spirit and dedication to advancing medical science.
Latest Patents
Chastain holds a patent for "Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules." This patent provides a comprehensive disclosure of anti-BTC antibodies, methods for producing these antibodies, pharmaceutical compositions that include them, and methods for their use. Additionally, the patent covers multi-specific binding molecules, such as bispecific antibodies, which incorporate a BTC binding moiety and an anti-VEGF binding moiety.
Career Highlights
Chastain is currently associated with Novartis AG, a leading global healthcare company. His role at Novartis allows him to work on cutting-edge research and development projects that aim to improve patient outcomes through innovative therapies. His expertise in antibody development is a valuable asset to the company.
Collaborations
Chastain collaborates with talented professionals in his field, including Chad Eric Bigelow and Ana Maria Carrion. These collaborations enhance the research efforts and contribute to the advancement of their shared goals in biotechnology.
Conclusion
James Edgar Chastain is a prominent inventor whose work on anti-betacellulin antibodies represents a significant advancement in medical research. His contributions to Novartis AG and collaborations with other experts highlight his commitment to innovation in the field.